Status:
RECRUITING
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Lead Sponsor:
University Health Network, Toronto
Conditions:
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Eligibility:
All Genders
Brief Summary
This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in...
Detailed Description
Radiopharmaceuticals is currently used for the treatment of metastatic cancer date. While radiopharmaceuticals are generally well tolerated, one of its most devastating long-term toxicities is the dev...
Eligibility Criteria
Inclusion
- ECOG 0-3
- Life expectancy \> 6 months
- Informed consent and willingness to undergoing serial genetic panel CHIP testing.
- Cohort Specific criteria
- Cohort A: PRRT completed within 5 years of enrolment
- Cohort B: PRRT planned to commence within 4 months of enrolment
- Cohort C: diagnosis of MDS or AML following prior PRRT.
Exclusion
- Unwillingness to provide blood sample and follow up as per protocol
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2029
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06510868
Start Date
August 1 2024
End Date
June 30 2029
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9